未登录 分享 收藏
分享 收藏
分享 收藏
Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: Phase I expansion results Yonemori, Kan; Yunokawa, Mayu; Matsumoto, Koji; Takehara, Kazuhiro; Hasegawa, Kosei; Hirashima, Yasuyuki; Kato, Hidenori; Ikezawa, Hiroki; Otake, Yohei; Yusa, Wataru; Miura, Takuma; Nishio, Shin 分享 收藏
分享 收藏
分享 收藏
Identification of novel gene fusions in high-grade serous ovarian carcinoma: implications for tumorigenesis and targeted therapy 鉴定高级别浆液性卵巢癌中新型基因融合：对肿瘤发生和靶向治疗的启示 Masago, Katsuhiro; Sasaki, Eiichi; Fujita, Yasuko; Fujita, Shiro; Horio, Yoshitsugu; Kuroda, Hiroaki; Ogasawara, Aiko; Tatsuno, Kenji; Aburatani, Hiroyuki; Oda, Katsutoshi; Hasegawa, Kosei; Matsushita, Hirokazu 分享 收藏
分享 收藏
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients DOMENICA：dostarlimab与单药化疗相比，用于一线治疗MMR缺乏的晚期子宫内膜癌患者 Cherifi, Francois; Ray-Coquard, Isabelle; Rubio, Maria Jesus; Paoletti, Xavier; Lorusso, Domenica; Choi, Chel Hun; Hasegawa, Kosei; Tan, David Shao Peng; Hudson, Emma; Davis, Alison; Tognon, Germana; Lheureux, Stephanie; Vardar Key, Mehmet Ali; Kurtz, Jean Emmanuel; Alexandre, Jerome; Joly, Florence 分享 收藏
分享 收藏
Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma 人表皮生长因子受体3在 epithelial ovarian cancer 患者中的表达：卵巢黏液性癌和透明细胞癌的潜在靶点 Sato, Sho; Shintani, Daisuke; Kaneda, Yuki; Nakamura, Ryuichi; Katoh, Tomomi; Yano, Mitsutake; Hanaoka, Mieko; Yagishita, Shigehiro; Yasuda, Masanori; Nagata, Motoko; Hasegawa, Kosei 分享 收藏
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial 帕姆单抗（Cemiplimab）在复发性宫颈癌中的疗效：EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 III期临床试验的最终总生存期分析 Oaknin, Ana; Monk, Bradley J.; de Melo, Andreia Cristina; Kim, Hee Seung; Kim, Yong Man; Lisyanskaya, Alla S.; Samouelian, Vanessa; Lorusso, Domenica; Damian, Fernanda; Chang, Chih-Long; Gotovkin, Evgeniy; Takahashi, Shunji; Ramone, Daniella; Mackowiak-Matejczyk, Beata; Polastro, Laura; Alia, Eva Maria Guerra; Colombo, Nicoletta; Makarova, Yulia; Goh, Jeffrey C.; Hasegawa, Kosei; Mora, Paulo; Pikiel, Joanna; Srivastav, Ratnesh; Rischin, Danny; Rubio, Maria Jesus; Perez, Javier; Yoo, Suk Young; Gao, Bo; Jamil, Shaheda; Seebach, Frank; Lowy, Israel; Mathias, Melissa; Fury, Matthew G.; Tewari, Krishnansu S. 分享 收藏
分享 收藏
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80) Dodarlimab单独或联合贝伐单抗与非铂类化疗在复发性妇科透明细胞癌中的II期随机研究 (DOVE/APGOT-OV7/ENGOT-ov80) Lee, Jung-Yun; Tan, David; Ray-Coquard, Isabelle; Lee, Jung Bok; Kim, Byoung Gie; Van Nieuwenhuysen, Els; Huang, Ruby Yun-Ju; Tse, Ka Yu; Gonzalez-Martin, Antonio; Scott, Clare; Hasegawa, Kosei; Wilkinson, Katie; Yang, Eun Yeong; Lheureux, Stephanie; Kristeleit, Rebecca 分享 收藏
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial Pembrolizumab或安慰剂联合放化疗，然后用pembrolizumab或安慰剂治疗新诊断的高危局部晚期宫颈癌 (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): 一项随机，双盲，安慰剂对照的3期试验的总生存期结果 Lorusso, Domenica; Xiang, Yang; Hasegawa, Kosei; Scambia, Giovanni; Leiva, Manuel; Ramos-Elias, Pier; Acevedo, Alejandro; Cvek, Jakub; Randall, Leslie; Gomes, Andrea Juliana Pereira de Santana; Mejia, Fernando Contreras; Helpman, Limor; Akilli, Huseyin; Lee, Jung-Yun; Saevets, Valeriya; Zagouri, Flora; Gilbert, Lucy; Sehouli, Jalid; Tharavichitkul, Ekkasit; Lindemann, Kristina; Colombo, Nicoletta; Chang, Chih-Long; Bednarikova, Marketa; Zhu, Hong; Oaknin, Ana; Christiaens, Melissa; Petru, Edgar; Usami, Tomoka; Liu, Peng; Yamada, Karin; Toker, Sarper; Keefe, Stephen M.; Pignata, Sandro; Duska, Linda R. 分享 收藏
Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial Pembrolizumab或安慰剂联合放化疗，然后用Pembrolizumab或安慰剂治疗新诊断的高危局部晚期宫颈癌 (ENGOT-cx11/GOG-3047/KEYNOTE-A18): 一项随机，双盲，3期临床试验 Lorusso, Domenica; Xiang, Yang; Hasegawa, Kosei; Scambia, Giovanni; Leiva, Manuel; Ramos-Elias, Pier; Acevedo, Alejandro; Sukhin, Vladyslav; Cloven, Noelle; Gomes, Andrea J. Pereira de Santana; Mejia, Fernando Contreras; Reiss, Ari; Ayhan, Ali; Lee, Jung-Yun; Saevets, Valeriya; Zagouri, Flora; Gilbert, Lucy; Sehouli, Jalid; Tharavichitkul, Ekkasit; Lindemann, Kristina; Lazzari, Roberta; Chang, Chih-Long; Lampe, Rudolf; Zhu, Hong; Oaknin, Ana; Christiaens, Melissa; Polterauer, Stephan; Usami, Tomoka; Li, Kan; Yamada, Karin; Toker, Sarper; Keefe, Stephen M.; Pignata, Sandro; Duska, Linda R. 分享 收藏
Integrated genomic/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin 整合的基因组/表观基因组分析对透明细胞卵巢癌的亚型进行分层，突出其细胞起源 Nishijima, Akira; Oda, Katsutoshi; Hasegawa, Kosei; Koso, Takahiro; Asada, Kayo; Ikeda, Yuji; Taguchi, Ayumi; Maeda, Daichi; Nagae, Genta; Tsuji, Shingo; Tatsuno, Kenji; Uehara, Yuriko; Kurosaki, Akira; Sato, Sho; Tanikawa, Michihiro; Sone, Kenbun; Mori, Mayuyo; Ikemura, Masako; Fujiwara, Keiichi; Ushiku, Tetsuo; Osuga, Yutaka; Aburatani, Hiroyuki 分享 收藏
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer Vergote, Ignace; Gonzalez-Martin, Antonio; Fujiwara, Keiichi; Kalbacher, Elsa; Bagameri, Andrea; Ghamande, Sharad; Lee, Jung-Yun; Banerjee, Susana; Maluf, Fernando Cotait; Lorusso, Domenica; Yonemori, Kan; Van Nieuwenhuysen, Els; Manso, Luis; Woelber, Linn; Westermann, Anneke; Covens, Allan; Hasegawa, Kosei; Kim, Byoung-Gie; Raimondo, Miriam; Bjurberg, Maria; Cruz, Felipe Melo; Angelergues, Antoine; Cibula, David; Barraclough, Lisa; Oaknin, Ana; Gennigens, Christine; Nicacio, Leo; Teng, Melinda Siew Leng; Whalley, Elizabeth; Soumaoro, Ibrahima; Slomovitz, Brian M. 分享 收藏
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial Pembrolizumab或安慰剂联合放化疗，然后用pembrolizumab或安慰剂治疗新诊断的高危局部晚期宫颈癌 (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): 一项随机，双盲，3期临床试验 Lorusso, Domenica; Xiang, Yang; Hasegawa, Kosei; Scambia, Giovanni; Leiva, Manuel; Ramos-Elias, Pier; Acevedo, Alejandro; Sukhin, Vladyslav; Cloven, Noelle; Gomes, Andrea J. Pereira de Santana; Mejia, Fernando Contreras; Reiss, Ari; Ayhan, Ali; Lee, Jung-Yun; Saevets, Valeriya; Zagouri, Flora; Gilbert, Lucy; Sehouli, Jalid; Tharavichitkul, Ekkasit; Lindemann, Kristina; Lazzari, Roberta; Chang, Chih-Long; Lampe, Rudolf; Zhu, Hong; Oaknin, Ana; Christiaens, Melissa; Polterauer, Stephan; Usami, Tomoka; Li, Kan; Yamada, Karin; Toker, Sarper; Keefe, Stephen M.; Pignata, Sandro; Duska, Linda R. 分享 收藏
Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study 尼拉帕尼在经过大量预处理的同源重组缺陷型卵巢癌患者中的应用: 一项多中心2期研究的最终结果 Aoki, Daisuke; Tabata, Tsutomu; Yanagida, Satoshi; Nakamura, Toshiaki; Kondo, Eiji; Hamanishi, Junzo; Harano, Kenichi; Hasegawa, Kosei; Hirasawa, Takeshi; Hori, Kensuke; Komiyama, Shinichi; Matsuura, Motoki; Nakai, Hidekatsu; Nakamura, Hiroko; Sakata, Jun; Takehara, Kazuhiro; Takekuma, Munetaka; Yokoyama, Yoshihito; Kase, Yoichi; Sumino, Shuuji; Soeda, Junpei; Kato, Ai; Suri, Ajit; Okamoto, Aikou; Sugiyama, Toru 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
.png){kind=icon}
分享.png){kind=icon}
收藏.png)
LANCET